GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » WuXi XDC Cayman Inc (FRA:L74) » Definitions » Tax Expense

WuXi XDC Cayman (FRA:L74) Tax Expense : €4.6 Mil (TTM As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is WuXi XDC Cayman Tax Expense?

WuXi XDC Cayman's tax expense for the months ended in Jun. 2023 was €2.1 Mil. Its tax expense for the trailing twelve months (TTM) ended in Jun. 2023 was €4.6 Mil.


WuXi XDC Cayman Tax Expense Historical Data

The historical data trend for WuXi XDC Cayman's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi XDC Cayman Tax Expense Chart

WuXi XDC Cayman Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Tax Expense
0.76 1.66 5.43 9.77

WuXi XDC Cayman Quarterly Data
Dec20 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23
Tax Expense Get a 7-Day Free Trial 1.72 - 2.48 2.07 -

WuXi XDC Cayman Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


WuXi XDC Cayman  (FRA:L74) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


WuXi XDC Cayman Tax Expense Related Terms

Thank you for viewing the detailed overview of WuXi XDC Cayman's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


WuXi XDC Cayman (FRA:L74) Business Description

Comparable Companies
Traded in Other Exchanges
Address
No. 11 Xinhui Ring Road, Xinwu, Jiangsu, Wuxi, CHN
Website
WuXi XDC Cayman Inc is a leading CRDMO focused on the global ADC and broader bioconjugate market and the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, It offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development and manufacturing. The company provides these services from proximately located, state-of-the-art laboratories and manufacturing facilities, leading to the significant reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development and manufacturing platform, its mission is to continuously enhance its platform, and propel and transform the development of the bioconjugate industry.

WuXi XDC Cayman (FRA:L74) Headlines

No Headlines